NeoGenomics, Inc. NEO
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +40.22%
- 1 year
- +68.78%
- Open
- 17.66
- Prev close
- 17.38
- Mkt cap
- 2.13B
- Vol
- 1.71M
- Avg vol
- 2.03M
- EPS
- -0.24
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.29
- High
- 17.66
- Forward P/E
- 52.42
- Beta
- 1.83
- Short ratio
- 5.78
- Inst. own
- 115.09%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 16, 2027
- 50-d avg
- 17.68
- 200-d avg
- 12.78
- 1y target
- 23.78
3M chart
Events in this range
- Oct 6, 2026Rating: BTIG · Neutral → Buy
- Oct 6, 2026Rating: Needham · Buy → Buy
- Oct 6, 2026Rating: StoneX · Buy → Buy
- Oct 28, 2026Earnings: 0.07; estimate 0.05546; surprise 26.22%
- Oct 29, 2026Rating: BTIG · Buy → Buy
- Oct 29, 2026Rating: TD Cowen · Buy → Buy
Signals (19)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| RSI: Overbought | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| RSI: Overbought | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
Key statistics
- Market cap
- 2.13B
- Enterprise value
- 2.56B
- Trailing P/E
- 0.00
- Forward P/E
- 52.42
- PEG ratio
- 2.09
- Price / sales
- 2.71
- Price / book
- 2.66
- EPS (TTM)
- -0.24
- Beta
- 1.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -4.10%
- Revenue (TTM)
- 787.75M
- Revenue growth
- 11.40%
- Free cash flow
- 4.80M
- Total cash
- 139.28M
- Total debt
- 449.14M
- Return on equity
- -3.94%
- Shares outstanding
- 129.39M
- Short % of float
- 12.98%
- 50-day average
- 17.68
- 200-day average
- 12.78
Analyst view
Consensus: buy
- Target (low)
- 19.00
- Target (mean)
- 23.78
- Target (high)
- 35.00
- Strong buy2
- Buy6
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 0.06455.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 0.06 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.05546 | 0.07 | +0.01 | +26.22% |
| Jul 28, 2026 | Jun 30, 2026 | 0.03355 | 0.05 | +0.02 | +49.03% |
| Apr 28, 2026 | Mar 31, 2026 | 0.00578 | 0.01 | 0.00 | +73.01% |
| Feb 17, 2026 | Dec 31, 2025 | 0.04 | 0.06 | +0.02 | +50.00% |
| Oct 28, 2025 | Sep 30, 2025 | 0.02 | 0.03 | +0.01 | +50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | TD Cowen | main | Buy | Buy |
| Oct 29, 2026 | BTIG | reit | Buy | Buy |
| Oct 6, 2026 | StoneX | main | Buy | Buy |
| Oct 6, 2026 | Needham | main | Buy | Buy |
| Oct 6, 2026 | BTIG | up | Neutral | Buy |
| Jul 29, 2026 | Needham | main | Buy | Buy |
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- neogenomics.com
News
- NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
- NEO Battery Reports Fiscal Year 2027 Second Quarter Results
- TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $23
- What NeoGenomics (NEO) Said on Its Q3 Earnings Call
- NeoGenomics Q3 2026 Earnings Call Transcript
- NeoGenomics Raises FY2026 Sales Guidance from $802.000M-$806.000M to $807.000M-$809.000M vs $805.827M Est
- NeoGenomics Q3 Adj. EPS $0.07 Beats $0.05 Estimate, Sales $209.254M Beat $207.328M Estimate
- NeoGenomics Reports Third Quarter 2026 Results
- NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
- NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
Your note
Sign in to keep a note on NEO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HANNAH ALISON L. | Director | Conversion of Exercise of derivative security | May 29, 2025 | 131,023 |
| HARRIS MELODY | Officer | Conversion of Exercise of derivative security | Feb 20, 2025 | 109,755 |
| KANOVSKY STEPHEN MICHAEL | Director | Conversion of Exercise of derivative security | May 31, 2026 | 75,421 |
| KELLY MICHAEL AARON | Director | Conversion of Exercise of derivative security | May 31, 2026 | 72,086 |
| OLIVO ALICIA C | General Counsel | Conversion of Exercise of derivative security | May 10, 2026 | 93,567 |
| SHERMAN JEFFREY SCOTT | Chief Financial Officer | Conversion of Exercise of derivative security | Feb 22, 2026 | 220,009 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.13% | 20,868,362 | 344.12M | Jun 29, 2026 |
| First Light Asset Management, LLC | 9.49% | 12,279,523 | 202.49M | Jun 29, 2026 |
| First Trust Advisors LP | 7.82% | 10,113,261 | 166.77M | Jun 29, 2026 |
| Greenhouse Funds, LLLP | 6.63% | 8,574,210 | 141.39M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.23% | 8,061,362 | 132.93M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.45% | 5,763,017 | 95.03M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.91% | 7,648,512 | 126.12M | Sep 29, 2026 |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 4.96% | 6,416,474 | 105.81M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.20% | 4,136,535 | 68.21M | Jun 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 3.15% | 4,081,051 | 67.30M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.60% | 3,359,516 | 55.40M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.31% | 2,985,348 | 49.23M | Jun 29, 2026 |